Clinical Trials Browser

Interferon alpha-2 × Dermatologic × Clear all

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Phase 3 Active not recruiting

1,150 enrolled 6 charts

Melanoma

NCT04093323 2026-02-25

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2 Terminated

Melanoma

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,673 enrolled 19 charts

Melanoma

NCT01359956 2023-04-11

SICOG 0109

Phase 3 Completed

269 enrolled 12 charts

Melanoma

NCT02323659 2022-01-13

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

Phase 4 Terminated

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT02339324 2021-02-24

Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

Phase 1 Completed

Melanoma

NCT03552549 2019-07-24

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Phase 2/3 Terminated

126 enrolled 9 charts

Melanoma

NCT01100528 2019-02-26

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Phase 2 Completed

38 enrolled 10 charts

Uveal Melanoma

NCT01943422 2018-04-03

12-107

Phase 1 Completed

Melanoma

NCT01409174 2017-05-31

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Phase 1 Terminated

Melanoma, Neoplasm Metastasis

NCT00204529 2017-05-03

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

Phase 3 Completed

Melanoma

NCT02829775 2017-01-09

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Phase 2/3 Completed

9 enrolled 7 charts

DermatologicGenitourinaryMyeloidOther hematologic neoplasm

Carcinoma, Renal Cell, Melanoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00613509 2016-04-14

Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma

Phase 2 Terminated

23 enrolled 14 charts

Melanoma, Neoplasms

NCT00723710 2015-08-26

Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)

299 enrolled 5 charts

Melanoma

NCT01462773 2015-01-13

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

Phase 1 Completed

16 enrolled 5 charts

Melanoma

NCT00026143 2013-06-05

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Phase 2 Completed

Melanoma

NCT00970996 2013-01-03

BCAA

Phase 1 Completed

Melanoma

NCT00002882 2011-12-13

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

Phase 3 Completed

Melanoma, Skin Neoplasms

NCT00963664 2009-09-09

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

Phase 2 Withdrawn

Melanoma

NCT00911443 2009-07-09

Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma

Phase 2 Completed

488 enrolled 12 charts

Melanoma

NCT00308607 2009-04-03

Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma

Phase 2 Completed

Melanoma, Neoplasm Metastasis